Industry

Arcturus to receive upfront payment of $200 million and more than $4 billion in potential development and commercial milestones 40% profit sharing for COVID-19 vaccines, up to double digit royalties for influenza, pandemic preparedness and three additional respiratory infectious disease vaccines Combines Arcturus’ self-amplifying mRNA vaccine technologies with CSL’s world-leading capabilities as a commercial scale … [Read more…]

Waist to Height Ratio, known to be correlated with insulin resistance & metabolic syndrome, was a predictor of weight loss response in the study based on a post-hoc analysis As previously reported, the LIGHT-UP study met its primary endpoint with 6 out of 10 responding to the treatment, achieving an average of 11% weight loss … [Read more…]

– New findings reinforce potential of company’s multi-omics capabilities and tools in immuno-oncology to address biopharma partners’ unique oncology drug development needs – SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics immuno-oncology capabilities and offerings will be presented at the Society for Immunotherapy of Cancer’s … [Read more…]

Increases Adjusted EBITDA Guidance to Exceed $175 million Net sales for the third quarter of $466 million, up 25 percent from prior year quarter Income from continuing operations for the third quarter of $18 million Adjusted EBITDA from continuing operations of $68 million, up 106 percent from prior year quarter Higher prices across all segments … [Read more…]

ST. PAUL, Minn.–(BUSINESS WIRE)–Christophe Beck, Ecolab Inc. chairman of the board and chief executive officer will address financial analysts at the Baird Global Industrial Conference on Tuesday, November 8. Ecolab will offer a webcast of Mr. Beck’s presentation. Details for the webcast are as follows: TIME:   12:25 pm Eastern Time       DATE: … [Read more…]

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, November 8, 2022, to discuss its third quarter 2022 financial results. The call will begin at 4:30 PM Eastern Time. It will be hosted by Masoud Toloue, the Company’s President … [Read more…]

Provides Executive Leadership Update SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the company has completed the expected tax-free spin-off of its OmniAb antibody discovery business which has become OmniAb, Inc., an independent publicly traded company. OmniAb will begin regular-way trading November 2, 2022 on NASDAQ under the stock ticker symbol “OABI.” Ligand continues to … [Read more…]

Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq EMERYVILLE, Calif.–(BUSINESS WIRE)–OmniAb, Inc. (NASDAQ: OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ: AHPA), resulting in … [Read more…]

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2022 financial results. “We are proud to share another quarter of strong commercial execution across our business, with excellent EnCompass traction following our launch … [Read more…]

INBRIJA® (levodopa inhalation powder) Q3 2022 U.S. net revenue of $7.8 million; 1% increase over Q3 2021 AMPYRA® (dalfampridine) Q3 2022 net revenue of $21.1 million; 5% increase over Q3 2021 $16.5M award and royalty/supply relief in AMPYRA arbitration case Special Meeting of Stockholders scheduled for November 4, 2022 Company will not use shares for December 2022 … [Read more…]